---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-195289"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:34:22.779330+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aeglea sells global rights to pegzilarginase to Immedica for $15M upfront + up to $100M milestones

## Summary
- Sold pegzilarginase (for Arginase 1 Deficiency) to Immedica for $15M upfront and up to $100M in milestone payments.
- Milestones contingent on European reimbursement decisions and FDA approval of pegzilarginase.
- Prior license agreement between Aeglea and Immedica terminated in connection with the sale.
- Proceeds net of expenses to be distributed to CVR holders from Spyre merger; first payments expected around Nov 14, 2023.
- Marketing Authorisation Application for pegzilarginase under review by the European Medicines Agency.

## SEC filing metadata
- accession: 0001193125-23-195289
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/0001193125-23-195289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/d473407d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-195289
- JSON: https://secwatch.observer/filing/0001193125-23-195289.json
- Plain text: https://secwatch.observer/filing/0001193125-23-195289.txt

## Key facts
- M&A Transactions
  Spyre Therapeutics, Inc. completed a disposition involving Immedica Pharma AB for initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing (closed 2023-07-27).
  - Action: disposition
  - Counterparty: Immedica Pharma AB
  - Consideration: initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing
  - Closing: 2023-07-27
  source text: Subject to the terms and conditions of the Purchase Agreement, at the closing of the transactions (the “Closing”) contemplated by the Purchase Agreement (the “Asset Purchase”), Immedica purchased from the Company its assets related to its research, development and manufacturing program for pegzilarginase for the treatment of Arginase-1 Deficiency as well as other therapeutic, prophylactic, palliative and diagnostic uses (the “Program,” and any pharmaceutical product containing, incorporating or comprising pegzilarginase, the “Product”) for an initial payment in cash of $15,000,000 due at Closing and up to $100,000,000 after the Closing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/0001193125-23-195289-index.htm
- Material Agreements
  Spyre Therapeutics, Inc. terminated License and Supply Agreement with Immedica (effective 2023-07-27).
  - Action: termination
  - Agreement: license
  - Counterparty: Immedica
  - Effective: 2023-07-27
  source text: As previously disclosed on March 21, 2021, the Company entered into a License and Supply Agreement (the “License Agreement”) with Immedica. In connection with the Asset Purchase and pursuant to the Purchase Agreement, the Company and Immedica terminated the License Agreement as of Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/0001193125-23-195289-index.htm
- Material Agreements
  Spyre Therapeutics, Inc. entered into Asset Purchase Agreement with Immedica Pharma AB valued at $15,000,000 due at Closing and up to $100,000,000 in Milestone Payments (effective 2023-07-27).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Immedica Pharma AB
  - Value: $15,000,000 due at Closing and up to $100,000,000 in Milestone Payments
  - Effective: 2023-07-27
  source text: On July 27, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the “Purchase Agreement”) with Immedica Pharma AB
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523195289/0001193125-23-195289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.